Reported treatment options for patients with relapsed/refractory CLL.
| . | Response rate in pilot trials* . | |
|---|---|---|
| Treatment regimen . | ORR, % . | CR, % . |
| * It should be noted that the pilot trials testing these regimens were phase II studies where the response rates reported are based on treatment of limited numbers of highly selected patients and can be profoundly influenced by the type(s) of prior treatment patients had received. | ||
| Alemtuzumab | 33–42 | 2–4 |
| Alemtuzumab and rituximab | 52 | 8 |
| Fludarabine, cyclophosphamide, rituximab (FCR) | 73 | 25 |
| Cyclophosphamide, fludarabine, alemtuzumab, rituximab (CFAR) | 65 | 24 |
| Lenalidomide | 32–47 | 5–9 |
| High-dose solumedrol ± rituximab | 55–100 | 40 |
| . | Response rate in pilot trials* . | |
|---|---|---|
| Treatment regimen . | ORR, % . | CR, % . |
| * It should be noted that the pilot trials testing these regimens were phase II studies where the response rates reported are based on treatment of limited numbers of highly selected patients and can be profoundly influenced by the type(s) of prior treatment patients had received. | ||
| Alemtuzumab | 33–42 | 2–4 |
| Alemtuzumab and rituximab | 52 | 8 |
| Fludarabine, cyclophosphamide, rituximab (FCR) | 73 | 25 |
| Cyclophosphamide, fludarabine, alemtuzumab, rituximab (CFAR) | 65 | 24 |
| Lenalidomide | 32–47 | 5–9 |
| High-dose solumedrol ± rituximab | 55–100 | 40 |